酪氨酸激酶SYK是肝纤维化的潜在治疗靶点
研究探讨脾酪氨酸激酶(SYK)促进肝纤维化的机制并评估其作为治疗靶点的潜力。在正常、HBV感染、HCV感染和非酒精性脂肪性肝炎肝组织中评估SYK定位及与纤维化的关联,并在细胞和三种动物模型中研究SYK拮抗对肝纤维生成的影响。结果显示SYK通过激活肝星状细胞促进肝纤维化,拮抗SYK可抑制纤维化并减少肝细胞癌发生。
要点
- 肝星状细胞和肝细胞中SYK蛋白与人类肝组织纤维化分期呈正相关。
- HBV或HCV感染显著增加肝细胞中SYK和细胞因子表达。
- SYK拮抗通过抑制肝星状细胞活化有效抑制肝纤维化,并减少动物模型中肝细胞癌发生。
核心结论
- SYK通过激活肝星状细胞促进肝纤维化,是肝纤维化和预防肝细胞癌发展的有吸引力的潜在治疗靶点。
研究设计与样本
- 研究评估了正常肝组织(n=36)、HBV感染肝组织(n=127)、HCV感染肝组织(n=22)和非酒精性脂肪性肝炎肝组织(n=30)中SYK的细胞定位及SYK表达与肝纤维生成的关联。
- 使用聚合酶链反应(PCR)阵列检测SYK敲低后肝星状细胞中转录因子表达变化。
- 在LX-2细胞、TWNT-4细胞、原代人肝星状细胞以及三种进行性纤维化/肝硬化动物模型(包括CCL4小鼠模型、二乙基亚硝胺(DEN)和大鼠胆管结扎(BDL)模型)中研究SYK拮抗对肝纤维生成的影响。
主要发现
- 肝星状细胞和肝细胞中SYK蛋白与人类肝组织纤维化分期呈正相关。
- HBV或HCV感染显著增加肝细胞中SYK和细胞因子表达。
- 细胞因子产生增加进一步诱导肝星状细胞中SYK表达和纤维化相关基因转录。
- 肝星状细胞中上调的SYK通过增加与肝星状细胞活化相关的特定转录因子表达促进肝星状细胞活化。
- SYK拮抗通过抑制肝星状细胞活化有效抑制肝纤维化,并减少动物模型中梗阻性黄疸和肝细胞癌发展。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Spleen tyrosine kinase (SYK) plays a critical role in immune cell signaling pathways and has been reported as a biomarker for human hepatocellular carcinoma (HCC). We sought to investigate the mechanism by which SYK promotes liver fibrosis and to evaluate SYK as a therapeutic target for liver fibrosis. We evaluated the cellular localization of SYK and the association between SYK expression and liver fibrogenesis in normal, hepatitis B virus (HBV)-infected, hepatitis C virus (HCV)-infected and non-alcoholic steatohepatitis (NASH) liver tissue (n=36, 127, 22 and 30, respectively). A polymerase chain reaction (PCR) array was used to detect the changes in transcription factor (TF) expression in hepatic stellate cells (HSCs) with SYK knockdown. The effects of SYK antagonism on liver fibrogenesis were studied in LX-2 cells, TWNT-4 cells, primary human HSCs, and three progressive fibrosis/cirrhosis animal models, including a CCL4 mouse model, and diethylnitrosamine (DEN) and bile duct ligation (BDL) rat models. We found that SYK protein in HSCs and hepatocytes correlated positively with liver fibrosis stage in human liver tissue. HBV or HCV infection significantly increased SYK and cytokine expression in hepatocytes. Increasing cytokine production further induced SYK expression and fibrosis-related gene transcription in HSCs. Up-regulated SYK in HSCs promoted HSC activation by increasing the expression of specific TFs related to activation of HSCs. SYK antagonism effectively suppressed liver fibrosis via inhibition of HSC activation, and decreased obstructive jaundice and reduced HCC development in animal models. Conclusion: SYK promotes liver fibrosis via activation of HSCs and is an attractive potential therapeutic target for liver fibrosis and prevention of HCC development. (Hepatology 2018).
引用
- Qu C, Zheng D, Li S, et al. Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology. 2018. PMID: 29537660. doi:10.1002/hep.29881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。